Moderna's vaccine is said to have an advantage over the competition.
It would offer better long-term protection against the serious effects of Covid-19 compared to that of Pfizer, concludes a study published Friday by the main health agency of the United States.
Researchers from the Centers for Disease Prevention and Control (CDC) analyzed a sample of nearly 3,700 adults hospitalized with Covid-19 associated with severe symptoms.
The study was conducted between March 11 and August 15, 2021, a period that precedes and includes the predominance of the Delta variant.
Read alsoCovid-19: follow the events of this Saturday live
Over the entire study period, Moderna's vaccine was 93% effective against hospitalizations, Pfizer's vaccine 88% effective and Johnson & Johnson's vaccine was 68% effective.
After 120 days, Moderna protects 92%, Pfizer 77%
But the loss of effectiveness of Pfizer's vaccine over time is particularly noticeable: its effectiveness rate drops from 91% over the period 14 to 120 days after injection to 77% for the period after 120 days.
In comparison, over the same periods, the effectiveness rate of Moderna's vaccine increased from 93% to 92%.
Several recent studies point in the same direction, confirming the apparent superiority of Moderna's vaccine over that of Pfizer.
